Susan Hogan to Creatinine
This is a "connection" page, showing publications Susan Hogan has written about Creatinine.
Connection Strength
0.183
-
Massicotte-Azarniouch D, Kotzen E, Todd S, Hu Y, Hogan SL, Jain K. Kidney thrombotic microangiopathy in lupus nephritis: Impact on treatment and prognosis. Lupus. 2022 Sep; 31(10):1175-1185.
Score: 0.047
-
Ibrahim ME, Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant CL, Bowles DW, George B, Wen X, Buckley B, Aleksunes L, Joy MS. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients. Eur J Clin Pharmacol. 2019 Jan; 75(1):51-57.
Score: 0.036
-
George B, Wen X, Mercke N, Gomez M, O'Bryant C, Bowles DW, Hu Y, Hogan SL, Joy MS, Aleksunes LM. Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity. Clin Pharmacol Ther. 2017 04; 101(4):510-518.
Score: 0.032
-
Joy MS, Boyette T, Hu Y, Wang J, La M, Hogan SL, Stewart PW, Falk RJ, Dooley MA, Smith PC. Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis. Eur J Clin Pharmacol. 2010 Nov; 66(11):1119-30.
Score: 0.020
-
Joy MS, Hilliard T, Hu Y, Hogan SL, Dooley MA, Falk RJ, Smith PC. Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy. 2009 Jan; 29(1):7-16.
Score: 0.018
-
Ferris M, Hogan SL, Chin H, Shoham DA, Gipson DS, Gibson K, Yilmaz S, Falk RJ, Jennette JC. Obesity, albuminuria, and urinalysis findings in US young adults from the Add Health Wave III study. Clin J Am Soc Nephrol. 2007 Nov; 2(6):1207-14.
Score: 0.017
-
Preston GA, Barrett CV, Alcorta DA, Hogan SL, Dinwiddie L, Jennette JC, Falk RJ. Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels. Nephron. 2002 Dec; 92(4):817-23.
Score: 0.012